Prilenia Therapeutics is a clinical-stage biotech company. The firm’s leader, Michael Hayden, MD, PhD., is a world-renowned scientist in Huntington’s Disease (HD) research. Dr. Hayden was the President of Global R&D and Chief Scientific Officer at Teva Pharmaceuticals, where he led the development of 35 new products towards approval in several major markets, predominantly in the central nervous system (CNS).
Michael Hayden and researchers with track records of success have formed a capable team aimed at conquering CNS debilitating and life-threatening diseases, including HD and Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s Disease.
The company has recently raised $68.5M in a Series A financing round to launch the planned Huntington Disease and ALS late-stage clinical trials. The funding has emanated from Forbion, accompanied by Morningside Venture Investments, Sectoral Asset Management, Talisman Capital Partners and ALS Investment Fund.
All These firms are leading Venture Capitals in the Life Science field.